A5050294061- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- Cancer, Hypoxia, and Metabolism
- Disability Education and Employment
- Ubiquitin and proteasome pathways
- Workplace Health and Well-being
- Cancer-related Molecular Pathways
- Elder Abuse and Neglect
- Retirement, Disability, and Employment
- Herpesvirus Infections and Treatments
- Musculoskeletal pain and rehabilitation
- Occupational Health and Safety Research
Oncode Institute
2020-2023
Leiden University Medical Center
2018-2023
Institute for Work & Health
2011
Background Cross-presentation of exogenous antigens in HLA-class I molecules by professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent murine studies show that several non-professional APCs, including cancer-associated fibroblasts (CAFs) also possess this capacity. Whether human CAFs are able to cross-present antigen, which molecular pathways involved process and how ultimately affects tumor-specific function unknown. Methods In study, we investigated the...
Background The presence of T cells and suppressive myeloid in epithelial ovarian cancer (EOC) correlate with good bad clinical outcome, respectively. This suggests that EOC may be sensitive to adoptive cell therapy autologous tumor-infiltrating lymphocytes (TIL), provided immunosuppression by myeloid-derived suppressor M2 macrophages is reduced. Platinum-based chemotherapy can alleviate such immunosuppression, potentially creating a window opportunity for cell-based immunotherapy. Methods We...
Background Adoptive cell therapy (ACT) with tumor-reactive T cells has shown consistent clinical efficacy. We evaluated the response to ACT in combination interferon alpha (IFNa) preconditioning patients stage IV metastatic melanoma, most of which were progressive on cytotoxic T-lymphocyte-associated protein 4 and/or programmed death 1 checkpoint blockade therapy. Methods Thirty-four treated ex vivo expanded tumor reactive cells, derived from mixed lymphocyte autologous cultures, or...
Treatment with anti-PD-1 immunotherapy does not lead to long-lasting clinical responses in approximately 60% of patients metastatic melanoma. These refractory patients, however, can still respond treatment tumour infiltrating lymphocytes (TIL) and interferon-alpha (IFNa). A combination TIL, pegylated-interferon-alpha (PEG-IFNa) is expected provide a safe, feasible effective therapy for melanoma, who are standard care options. Patients treated two phases. In phase I, the safety TIL assessed...
<p>More detailed information on: 1) Immune-fluorescent staining, 2) Mass spectrometry, 3) MLTC and TIL cultures.</p>
<p>Expression of tumor associated antigens in early and later metastatic lesions.</p>
<p>Putative neoantigens in early and later metastatic lesions.</p>
<p>HLA class II expression and recognition of early later metastatic lesion- derived tumor cells from patient Mel5 by CD4+ CD8⁺ T cells.</p>
<p>Immunohistochemical staining of proteins involved in T cell recognition and/or inhibition.</p>
<p>HLA class I and II expression on melanoma cell lines derived from early later metastatic lesions.</p>
<p>T cell recognition of melanoma lines derived from early and later metastatic lesions.</p>
<p>Putative neoantigens in early and later metastatic lesions.</p>
<p>Immunohistochemical staining of proteins involved in T cell recognition and/or inhibition.</p>
<p>Expression of tumor associated antigens in early and later metastatic lesions.</p>
<p>T cell recognition of melanoma lines derived from early and later metastatic lesions.</p>
<p>HLA class II expression and recognition of early later metastatic lesion- derived tumor cells from patient Mel5 by CD4+ CD8⁺ T cells.</p>
<p>HLA class I and II expression on melanoma cell lines derived from early later metastatic lesions.</p>
<p>More detailed information on: 1) Immune-fluorescent staining, 2) Mass spectrometry, 3) MLTC and TIL cultures.</p>